Concepts (140)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Myeloma | 21 | 2024 | 307 | 10.970 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 11 | 2023 | 878 | 3.780 |
Why?
|
| Neoplasm, Residual | 7 | 2024 | 162 | 2.420 |
Why?
|
| Dexamethasone | 8 | 2023 | 326 | 1.630 |
Why?
|
| Peripheral Nervous System Diseases | 2 | 2022 | 85 | 1.580 |
Why?
|
| Transplantation, Autologous | 9 | 2023 | 330 | 1.350 |
Why?
|
| Hematologic Neoplasms | 2 | 2022 | 329 | 1.240 |
Why?
|
| Waldenstrom Macroglobulinemia | 2 | 2024 | 10 | 1.100 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 2 | 2022 | 8 | 1.070 |
Why?
|
| Antibodies, Bispecific | 1 | 2023 | 21 | 0.920 |
Why?
|
| Geriatric Assessment | 3 | 2020 | 166 | 0.870 |
Why?
|
| Paraproteinemias | 1 | 2022 | 13 | 0.860 |
Why?
|
| Serotonin and Noradrenaline Reuptake Inhibitors | 1 | 2021 | 1 | 0.830 |
Why?
|
| Duloxetine Hydrochloride | 1 | 2021 | 2 | 0.830 |
Why?
|
| Clinical Decision-Making | 2 | 2020 | 257 | 0.780 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 9 | 2023 | 2436 | 0.780 |
Why?
|
| Oligopeptides | 2 | 2021 | 179 | 0.770 |
Why?
|
| Agammaglobulinemia | 1 | 2020 | 20 | 0.760 |
Why?
|
| Amyloidosis | 1 | 2022 | 115 | 0.750 |
Why?
|
| Cancer Survivors | 1 | 2021 | 85 | 0.730 |
Why?
|
| Humans | 36 | 2024 | 86617 | 0.720 |
Why?
|
| Daunorubicin | 1 | 2019 | 78 | 0.710 |
Why?
|
| Antineoplastic Agents | 2 | 2021 | 2358 | 0.680 |
Why?
|
| Cytarabine | 1 | 2019 | 218 | 0.680 |
Why?
|
| Interdisciplinary Communication | 1 | 2019 | 130 | 0.670 |
Why?
|
| Bacterial Infections | 1 | 2020 | 182 | 0.670 |
Why?
|
| Disease Management | 2 | 2020 | 327 | 0.650 |
Why?
|
| Remission Induction | 1 | 2019 | 722 | 0.620 |
Why?
|
| Preoperative Care | 1 | 2019 | 394 | 0.600 |
Why?
|
| Patient Care Team | 1 | 2019 | 280 | 0.600 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2020 | 295 | 0.590 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2020 | 763 | 0.580 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2020 | 508 | 0.540 |
Why?
|
| Budd-Chiari Syndrome | 1 | 2015 | 9 | 0.540 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 375 | 0.530 |
Why?
|
| Stem Cell Transplantation | 3 | 2021 | 183 | 0.530 |
Why?
|
| Precision Medicine | 1 | 2019 | 395 | 0.520 |
Why?
|
| Attitude of Health Personnel | 1 | 2020 | 636 | 0.520 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2020 | 581 | 0.510 |
Why?
|
| Practice Guidelines as Topic | 1 | 2021 | 1034 | 0.490 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2020 | 860 | 0.440 |
Why?
|
| Physicians | 1 | 2020 | 673 | 0.430 |
Why?
|
| Venous Thrombosis | 1 | 2015 | 243 | 0.430 |
Why?
|
| Middle Aged | 10 | 2023 | 25017 | 0.420 |
Why?
|
| Aged | 9 | 2021 | 18402 | 0.400 |
Why?
|
| Flow Cytometry | 2 | 2024 | 679 | 0.370 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2024 | 456 | 0.330 |
Why?
|
| Proportional Hazards Models | 2 | 2020 | 858 | 0.320 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2017 | 1075 | 0.320 |
Why?
|
| Adult | 7 | 2021 | 25640 | 0.290 |
Why?
|
| Male | 9 | 2023 | 40958 | 0.280 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2024 | 170 | 0.270 |
Why?
|
| Female | 9 | 2023 | 44509 | 0.270 |
Why?
|
| Lung Neoplasms | 1 | 2017 | 2262 | 0.250 |
Why?
|
| Aged, 80 and over | 3 | 2020 | 6501 | 0.240 |
Why?
|
| Disease-Free Survival | 2 | 2023 | 1204 | 0.230 |
Why?
|
| Surveys and Questionnaires | 2 | 2022 | 2501 | 0.230 |
Why?
|
| CD3 Complex | 1 | 2023 | 135 | 0.230 |
Why?
|
| Lymphoma, B-Cell | 1 | 2024 | 103 | 0.220 |
Why?
|
| Hypercalcemia | 1 | 2023 | 59 | 0.220 |
Why?
|
| Imides | 1 | 2022 | 26 | 0.220 |
Why?
|
| Proteasome Inhibitors | 1 | 2022 | 51 | 0.220 |
Why?
|
| Bortezomib | 1 | 2022 | 76 | 0.210 |
Why?
|
| Melphalan | 1 | 2022 | 97 | 0.210 |
Why?
|
| Bone Marrow | 1 | 2024 | 435 | 0.210 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2023 | 151 | 0.210 |
Why?
|
| Cyclophosphamide | 1 | 2022 | 299 | 0.200 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2022 | 71 | 0.200 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2022 | 166 | 0.200 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2021 | 74 | 0.190 |
Why?
|
| Bone Marrow Examination | 1 | 2020 | 48 | 0.190 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2020 | 66 | 0.180 |
Why?
|
| Health Planning Guidelines | 1 | 2019 | 24 | 0.180 |
Why?
|
| Treatment Outcome | 3 | 2023 | 7990 | 0.180 |
Why?
|
| T-Lymphocytes | 2 | 2023 | 1195 | 0.180 |
Why?
|
| Asparaginase | 1 | 2019 | 35 | 0.180 |
Why?
|
| Philadelphia Chromosome | 1 | 2019 | 38 | 0.180 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2020 | 86 | 0.180 |
Why?
|
| Health Plan Implementation | 1 | 2019 | 56 | 0.170 |
Why?
|
| Health Care Surveys | 1 | 2020 | 278 | 0.170 |
Why?
|
| Standard of Care | 1 | 2019 | 78 | 0.170 |
Why?
|
| Reference Standards | 1 | 2019 | 159 | 0.170 |
Why?
|
| Chromosome Aberrations | 1 | 2020 | 387 | 0.170 |
Why?
|
| Allografts | 1 | 2019 | 172 | 0.170 |
Why?
|
| Sex Characteristics | 1 | 2020 | 319 | 0.160 |
Why?
|
| Cognitive Dysfunction | 1 | 2020 | 132 | 0.160 |
Why?
|
| Palliative Care | 1 | 2019 | 257 | 0.150 |
Why?
|
| Neoplasms | 2 | 2023 | 2898 | 0.150 |
Why?
|
| Sex Factors | 1 | 2020 | 1054 | 0.150 |
Why?
|
| Polyethylene Glycols | 1 | 2019 | 363 | 0.150 |
Why?
|
| Transplantation, Homologous | 1 | 2019 | 996 | 0.150 |
Why?
|
| Pilot Projects | 1 | 2020 | 839 | 0.150 |
Why?
|
| Retrospective Studies | 4 | 2023 | 8477 | 0.150 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2022 | 930 | 0.150 |
Why?
|
| Leukocyte Count | 1 | 2017 | 220 | 0.150 |
Why?
|
| Prognosis | 2 | 2023 | 3675 | 0.140 |
Why?
|
| Patient Selection | 1 | 2019 | 685 | 0.140 |
Why?
|
| Splanchnic Circulation | 1 | 2015 | 16 | 0.130 |
Why?
|
| Disease Progression | 1 | 2020 | 1531 | 0.130 |
Why?
|
| Sensitivity and Specificity | 1 | 2020 | 1991 | 0.130 |
Why?
|
| Body Weight | 1 | 2017 | 459 | 0.130 |
Why?
|
| Neutrophils | 1 | 2017 | 307 | 0.130 |
Why?
|
| Lymphocytes | 1 | 2017 | 464 | 0.130 |
Why?
|
| Time Factors | 2 | 2020 | 5209 | 0.120 |
Why?
|
| Serial Publications | 1 | 2014 | 2 | 0.120 |
Why?
|
| Journal Impact Factor | 1 | 2014 | 14 | 0.120 |
Why?
|
| Quality of Life | 1 | 2022 | 1583 | 0.120 |
Why?
|
| Science | 1 | 2014 | 34 | 0.120 |
Why?
|
| Reproduction | 1 | 2014 | 195 | 0.110 |
Why?
|
| Prospective Studies | 1 | 2020 | 4212 | 0.100 |
Why?
|
| United States | 1 | 2024 | 6665 | 0.100 |
Why?
|
| Child | 1 | 2019 | 6926 | 0.080 |
Why?
|
| Risk Factors | 1 | 2015 | 5417 | 0.060 |
Why?
|
| Young Adult | 1 | 2015 | 5974 | 0.060 |
Why?
|
| Cell Transplantation | 1 | 2023 | 47 | 0.060 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2023 | 138 | 0.050 |
Why?
|
| Adolescent | 1 | 2015 | 8979 | 0.050 |
Why?
|
| Adrenal Insufficiency | 1 | 2022 | 23 | 0.050 |
Why?
|
| Tumor Burden | 1 | 2023 | 288 | 0.050 |
Why?
|
| Vaccines, Synthetic | 1 | 2022 | 55 | 0.050 |
Why?
|
| Antibody Formation | 1 | 2022 | 171 | 0.050 |
Why?
|
| Immunity, Cellular | 1 | 2022 | 177 | 0.050 |
Why?
|
| 5-Methylcytosine | 1 | 2022 | 112 | 0.050 |
Why?
|
| Autografts | 1 | 2020 | 28 | 0.050 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2022 | 159 | 0.050 |
Why?
|
| Smoldering Multiple Myeloma | 1 | 2020 | 3 | 0.050 |
Why?
|
| Antibodies, Viral | 1 | 2022 | 293 | 0.050 |
Why?
|
| Vaccination | 1 | 2022 | 254 | 0.050 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2020 | 70 | 0.050 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2020 | 69 | 0.050 |
Why?
|
| Activities of Daily Living | 1 | 2020 | 204 | 0.040 |
Why?
|
| Population Surveillance | 1 | 2020 | 219 | 0.040 |
Why?
|
| Global Health | 1 | 2020 | 193 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2023 | 1313 | 0.040 |
Why?
|
| Diagnostic Imaging | 1 | 2020 | 469 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 1169 | 0.030 |
Why?
|
| PubMed | 1 | 2014 | 12 | 0.030 |
Why?
|
| Phenotype | 1 | 2020 | 2378 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 2705 | 0.030 |
Why?
|
| Research | 1 | 2014 | 253 | 0.030 |
Why?
|